BioCryst Pharmaceuticals (NASDAQ: BCRX) recently received a number of ratings updates from brokerages and research firms:
- 9/10/2026 – BioCryst Pharmaceuticals was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $11.00 price target on the stock, down from $13.00.
- 9/8/2026 – BioCryst Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $16.00 price target on the stock.
- 8/29/2026 – BioCryst Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 8/27/2026 – BioCryst Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
- 8/8/2026 – BioCryst Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “strong-buy”.
- 8/6/2026 – BioCryst Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $14.00 to $13.00. They now have an “outperform” rating on the stock.
- 8/6/2026 – BioCryst Pharmaceuticals had its price target lowered by Wedbush from $21.00 to $20.00. They now have an “outperform” rating on the stock.
BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes orally administered medicines for rare diseases. The company focuses on treatments that address significant unmet medical needs, using expertise in small-molecule drug discovery and development.
BioCryst’s primary commercial product is ORLADEYO (berotralstat), an oral, once-daily medication used to prevent hereditary angioedema attacks in adults and pediatric patients ages 12 and older.
See Also
- Five stocks we like better than BioCryst Pharmaceuticals
- Digging for Value: Alpha Metallurgical Resources Insider Buys Big
- Smart Money Shifts: U.S. Bancorp Pairs Tech With Yield
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
Receive News & Ratings for BioCryst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
